Detailed introduction of Anweili brand Mobosetinib/Mobosetinib

Mobocertinib (Mobocertinib) trade nameExkivity, is a new generation of oral small molecule targeted therapy specifically targeted at adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. This mutant EGFR is usually resistant to traditional EGFR-TKIs (such as gefitinib, erlotinib, etc.), and treatment options are extremely limited. Mobosetinibis the world's first targeted drug approved by the U.S.FDA for use in this special mutation population, marking a new stage of precision medicine in the treatment of EGFR exon 20 mutated lung cancer.

The mechanism of action of mobosetinib is to selectively inhibit abnormally activated EGFR mutants, especially exon 20 insertion mutations, which account for approximately 4% to 12% of all EGFR mutations, but the prognosis of patients is generally poor. Mobosetinibcovalently bindsthe kinase domain of EGFR to block activation of its signaling pathway, thereby inhibiting tumor cell proliferation and survival. It exhibits different action sites and affinity properties from traditional EGFR inhibitors. It has a low affinity for normal EGFR, which helps reduce certain side effects.

The standard usage of mobosetinib is 160 mg orally daily, which can be taken on an empty stomach or with food. Generally, no special dose adjustment is required. Its capsule dosage form allows patients to complete treatment at home, improving compliance and quality of life. According to the results of the pivotal Phase III EXCLAIM study, mobosertinib achieved an objective response rate (ORR) of 28%, a median progression-free survival (PFS) of 7.3 months, and a median overall survival (OS) of 24.0 months in NSCLC patients who had previously received platinum-containing chemotherapy and carried EGFR 20 insertion mutations, showing significant therapeutic benefit in the same patient population.

In terms of safety, the most common adverse reactions of mobosetinib include diarrhea, rash, stomatitis, nausea, fatigue, etc. Diarrhea, in particular, is a dose-dependent side effect, and some patients may need to temporarily stop taking the drug or reduce the dose. In severe cases (such as grade 3 or above diarrhea), antidiarrheal drugs and fluid support therapy should be considered. Since mobosetinib may also affect QT interval prolongation and induce arrhythmia, it is recommended to conduct a baseline electrocardiogram assessment before use, and to regularly monitor electrocardiogram and electrolyte levels during treatment. Patients with a known history of heart disease or who are being treated with multiple medications should be strictly monitored under the guidance of a physician.

The clinical value of mobosetinib is not only reflected in its targeting and efficacy, but also in its precise intervention path for EGFR exon 20 mutations, a long-neglected target. In the past, most patients carrying this mutation could only receive chemotherapy or immunotherapy, but the response rate was low, the survival period was short, and the clinical needs were urgently unmet. The advent of mobosetinib has given this special group of patients a new option to extend survival and improve symptoms, especially when they are not suitable for chemotherapy or have become resistant to chemotherapy.

In summary, mobosetinib is a major therapeutic advance for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. Based on precise targets, it fills the gaps in previous treatments through its convenient oral administration and controllable safety, and provides a new treatment paradigm for clinical practice.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib